Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Álex Bataller, Alexandre Bazinet, Courtney D. DiNardo, et al.
Blood Advances (2023) Vol. 8, Iss. 4, pp. 927-935
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine
Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, et al.
Blood (2024) Vol. 144, Iss. 21, pp. 2211-2222
Open Access | Times Cited: 23
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Hartmut Döhner, Courtney D. DiNardo, Frederick Appelbaum, et al.
Blood (2024) Vol. 144, Iss. 21, pp. 2169-2173
Closed Access | Times Cited: 20
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
Dana Alawieh, Leila Cysique-Foinlan, Christophe Willekens, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Current status and research directions in acute myeloid leukemia
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Venetoclax Resistance in Acute Myeloid Leukemia
Sylvain Garciaz, Marie‐Anne Hospital, Yves Collette, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1091-1091
Open Access | Times Cited: 8
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 1
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
Rabia Shahswar, Razif Gabdoulline, K Krueger, et al.
Leukemia (2025)
Open Access
Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
Giovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, et al.
American Journal of Hematology (2025)
Open Access
VenEx precisely predicts ven-aza response
Pamela S. Becker
Blood (2025) Vol. 145, Iss. 4, pp. 353-354
Closed Access
A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia with Azacitidine plus Venetoclax
Joseph Brandwein, David Page, Elena Liew, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Open Access
Therapeutic application of allogeneic hematopoietic stem cells in childhood acute myeloid leukemia
Yin Luo
Deleted Journal (2025), pp. 1-16
Closed Access
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Jad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
Deleted Journal (2024) Vol. 1, Iss. 3, pp. 100017-100017
Open Access | Times Cited: 3
Beat-AML 2024 ELN-Refined Risk Stratification for Older Adults with Newly Diagnosed AML Given Lower-Intensity Therapy
Fieke W. Hoff, William Blum, Ying Huang, et al.
Blood Advances (2024) Vol. 8, Iss. 20, pp. 5297-5305
Open Access | Times Cited: 3
Acute myeloid leukemia management and research in 2025
Hagop M. Kantarjian, Courtney D. DiNardo, Tapan M. Kadia, et al.
CA A Cancer Journal for Clinicians (2024)
Open Access | Times Cited: 3
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent
Naseema Gangat, Azeem Elbeih, Nour Ghosoun, et al.
American Journal of Hematology (2024)
Open Access | Times Cited: 3
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation
Jayastu Senapati, Hagop M. Kantarjian, Fadi G. Haddad, et al.
American Journal of Hematology (2024) Vol. 100, Iss. 2, pp. 249-259
Closed Access | Times Cited: 3
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study
Olga Salamero, Antonieta Molero, Jose Antonio Pérez‐Simón, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 7, pp. e487-e498
Closed Access | Times Cited: 2
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
Jennifer Marvin‐Peek, Jason S. Gilbert, Daniel A. Pollyea, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 9, pp. 1790-1801
Closed Access | Times Cited: 2
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations
Rabia Shahswar, Arnold Ganser
Expert Review of Hematology (2024) Vol. 17, Iss. 10, pp. 723-739
Closed Access | Times Cited: 2
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms
Jayastu Senapati, Sanam Loghavi, Guillermo Garcia‐Manero, et al.
Haematologica (2024)
Open Access | Times Cited: 2
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Pasquale Niscola, Valentina Gianfelici, Gianfranco Catalano, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6632-6658
Open Access | Times Cited: 1
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis
Samuel Urrutia, Hagop M. Kantarjian, Farhad Ravandi‐Kashani, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 1
A simplified risk model for pretreatment stratification of newly diagnosed acute myeloid leukemia patients treated with venetoclax and azacitidine
N Islam, Jamie S. Reuben, Justin Dale, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Maximilian Fleischmann, Madlen Jentzsch, Annamaria Brioli, et al.
Annals of Hematology (2024)
Open Access
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multi-center Cohort Study
Guopan Yu, Yu Zhang, Sijian Yu, et al.
Clinical Cancer Research (2024) Vol. 31, Iss. 1, pp. 87-97
Closed Access
Page 1 - Next Page

Scroll to top